Alphamab Oncology
Climate Impact & Sustainability Data (2023)
Reporting Period: 2023
Environmental Metrics
Total Carbon Emissions:12,760.81 tonnes of CO2 equivalent
Scope 1 Emissions:3,969.51 tonnes of CO2 equivalent
Scope 2 Emissions:8,791.30 tonnes of CO2 equivalent
Total Energy Consumption:35,063.56 '000kWh
Water Consumption:179,999.85 m3
Waste Generated:273.65 tons
Carbon Intensity:50.05 tonnes of CO2 equivalent/million RMB
ESG Focus Areas
- Environmental Management
- Social Responsibility
- Corporate Governance
Environmental Achievements
- Reduced greenhouse gas emission intensity by 76.04% compared to 2020.
- Reduced energy consumption intensity by 72.46% compared to 2020.
- Reduced water consumption intensity by 71.42% compared to 2020.
- Reduced total waste emissions by 24.05% compared to 2022.
Social Achievements
- Donated over 220,000 vials of ENWEIDA (Envafolimab Injection), valued at RMB 132 million.
- Organized various employee engagement activities, including fire drills, chemical leakage drills, and employee conferences.
- Implemented a comprehensive employee training program with 100% employee participation.
- Promoted over 50 employees (12% of the workforce).
Governance Achievements
- Established a three-level ESG management structure (Board, ESG Working Committee, ESG Working Group).
- Implemented a robust risk control system with regular audits.
- Conducted anti-corruption training for all directors and employees.
- Secured over 33 authorized patents.
Climate Goals & Targets
Environmental Challenges
- Climate change-related risks (extreme weather, policy and legal risks, technical and market risks).
- Potential supply chain disruptions.
Mitigation Strategies
- Developed a Plan on On-Site Handling of Extreme Weather Incidents.
- Implemented measures to promote domestic material sourcing (over 50% domestically sourced materials).
- Established a robust supplier management system with audits and training.
Supply Chain Management
Supplier Audits: 21 supplier audits conducted in 2023
Responsible Procurement
- Sunshine Agreement
- Prioritization of suppliers with exemplary environmental and social performance
- Promotion of domestic materials
Climate-Related Risks & Opportunities
Physical Risks
- Extreme weather events (droughts, typhoons, floods, high temperatures)
Transition Risks
- Policy & legal risks, technical risks, market risks
Reporting Standards
Frameworks Used: HKEX ESG Reporting Guide
Sustainable Products & Innovation
- Envafolimab Injection (subcutaneous injection, reducing hospital visits)
Awards & Recognition
- 2023 Top 20 Chinese Pharmaceutical Listed Companies in ESG Competitiveness
- 2023 Top 100 Chinese Pharmaceutical Innovative Enterprises